Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
LDR Spine USA Mobi-C(R) Cervical Disc Prosthesis IDE
This study has been completed.
Sponsored by: LDR Spine USA
Information provided by: LDR Spine USA
ClinicalTrials.gov Identifier: NCT00389597
  Purpose

The purpose of this investigation is to establish the safety and effectiveness of the LDR Spine Mobi-C® Cervical Disc Prosthesis which is an anterior cervical interbody mechanical device. The primary objective of the study is to evaluate the overall success rate of the investigational device as compared to the control in the treatment of patients with symptomatic DDD with radiculopathy or myeloradiculopathy at one or two adjacent levels. Patients should be without prior cervical fusion between C3 and C7 and unresponsive to non-operative conservative treatment for six weeks after symptom onset or have the presence of progressive symptoms or signs of nerve/spinal cord compression despite continued non-operative conservative treatment.


Condition Intervention Phase
Degenerative Disc Disease
Device: Cervical Artificial Disc
Phase II

Drug Information available for: Meloxicam
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind (Investigator), Active Control, Single Group Assignment, Efficacy Study
Official Title: LDR Spine USA Mobi-C(R) Cervical Disc Prosthesis IDE

Further study details as provided by LDR Spine USA:

Primary Outcome Measures:
  • Composite definition of Study Success [ Time Frame: 2 Years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 600
Study Start Date: April 2006
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: Cervical Artificial Disc
    Cervical artificial disc mechanical device
Detailed Description:

Objectives of the Investigation

The purpose of this investigation is to establish the safety and effectiveness of the LDR Spine Mobi-C® Cervical Disc Prosthesis which is an anterior cervical interbody mechanical device. The primary objective of the study is to evaluate the overall success rate of the investigational device as compared to the control in the treatment of patients with symptomatic DDD with radiculopathy or myeloradiculopathy at one or two adjacent levels. Patients should be without prior cervical fusion between C3 and C7 and unresponsive to non-operative conservative treatment for six weeks after symptom onset or have the presence of progressive symptoms or signs of nerve/spinal cord compression despite continued non-operative conservative treatment.

A maximum of 25 centers will participate in the study. Enrollment will be monitored to ensure that each center performs an adequate number of cases and no one center contributes a disproportionate number of cases to optimize poolability.

Study Design Rationale

The study is a prospective, randomized, multi-center, concurrently controlled investigation, in which the study device will be compared to the control treatment consisting of conventional anterior cervical discectomy and fusion (ACDF) in accordance with the Smith-Robinson procedure. Patients will be followed for two years postsurgery (primary endpoint) and annually thereafter.

Duration of the Investigation

Patients will be followed post-operatively at 6 weeks, and 3-, 6-, 12-, 18-, and 24-months. After 24 months, patients will continue to be followed annually.

Design Techniques to Avoid Bias

To eliminate selection bias, investigational and control comparison groups will be assigned at random.

Institutional Review Board

No clinical studies will begin without documented approval of the clinical investigation by the Institutional Review Board (IRB) affiliated with the study center.

  Eligibility

Ages Eligible for Study:   18 Years to 69 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18-69 years.
  2. Diagnosis of radiculopathy or myeloradiculopathy of the cervical spine, with pain, paresthesias or paralysis in a specific nerve root distribution C3 through C7, including at least one of the following:

    • Neck and/or arm pain (at least 30mm on the 100mm VAS scale).
    • Decreased muscle strength of at least one level on the clinical evaluation 0 to 5 scale.
    • Abnormal sensation including hyperesthesia or hypoesthesia; and/or
    • Abnormal reflexes
  3. Symptomatic at one or two adjacent levels from C3 to C7;
  4. Radiographically determined pathology at one or two adjacent level(s) to be treated correlating to primary symptoms including at least one of the following:

    • Decreased disc height on radiography, CT, or MRI in comparison to a normal adjacent disc.
    • Degenerative spondylosis on CT or MRI.
    • Disc herniation on CT or MRI;
  5. Neck Disability Index Score of ≥15/50 or ≥30%;
  6. Unresponsive to non-operative, conservative treatment (rest, heat, electrotherapy, physical therapy, chiropractic care and/or analgesics) for:

    • Approximately six weeks from radiculopathy or myeloradiculopathy symptom onset; or
    • Have the presence of progressive symptoms or signs of nerve root/spinal cord compression despite continued non-operative conservative treatment.

Note: Not a complete listing

Exclusion Criteria:

  1. Reported to have an active systemic infection or infection at the operative site;
  2. Reported to have a history of or anticipated treatment for active systemic infection, including HIV or Hepatitis C;
  3. More than one immobile vertebral level between C1 to C7 from any cause including but not limited to congenital abnormalities and osteoarthritic "spontaneous" fusions;
  4. Previous trauma to the C3 to C7 levels resulting in significant bony or disco-ligamentous cervical spine injury;
  5. Reported to have had any prior spine surgery at the operative level;
  6. Reported to have had prior cervical fusion procedure at any level;
  7. Axial neck pain in the absence of other symptoms of radiculopathy or myeloradiculopathy justifying the need for surgical intervention;
  8. Disc height less than 3mm as measured from the center of the disc in a neutral position and disc height less than 20% of the anterior-posterior width of the inferior vertebral body;
  9. Radiographic confirmation of severe facet joint disease or degeneration;

Note: Not a complete listing

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00389597

Locations
United States, Arizona
Texas Back Institute-West
Phoenix, Arizona, United States, 85015
United States, California
Spine Institute at St. John's Health Center
Santa Monica, California, United States, 90404
University of California- Davis Medical Center
Sacramento, California, United States, 95817
Stanford University
Stanford, California, United States, 94305
Massoudi & Jackson Neurosurgical Association
Laguna Hills, California, United States, 92653
Eisenhower Medical Center
Rancho Mirage, California, United States, 92270
Southern California Institute of Neurological Surgery
Escondido, California, United States, 92122
Memorial Orthopaedic Surgical Group
Long Beach, California, United States, 90806
United States, Colorado
Panorama Orthopedics and Spine Care
Golden, Colorado, United States, 80401
United States, Florida
Southeastern Clinical Research
Orlando, Florida, United States, 32804
United States, Indiana
Orthopaedics North East
Fort Wayne, Indiana, United States, 46825
United States, Louisiana
Spine Institute of Louisiana
Shreveport, Louisiana, United States, 71101
United States, Maryland
GBMC Healthcare
Baltimore, Maryland, United States, 21204
United States, Michigan
University Neurologic Systems
Detroit, Michigan, United States, 48201
St. Mary's of Saginaw Field Neurosciences Institute
Saginaw, Michigan, United States, 48604
United States, New York
Orthopedic Spine Care of Long Island
Melville, New York, United States, 11747
Simmons Orthopaedics and Spine Associates
Buffalo, New York, United States, 14201
United States, Ohio
The Cleveland Clinic
Cleveland, Ohio, United States, 44195
United States, Oklahoma
Oklahoma Spine & Brain Institute
Tulsa, Oklahoma, United States, 74132
United States, Texas
Austin Brain and Spine
Austin, Texas, United States, 78701
Texas Spine and Joint Hospital
Tyler, Texas, United States, 75701
Texas Back Institute
Plano, Texas, United States, 75093
West Texas Spine
Odessa, Texas, United States, 79761
Foundation Surgical Hospital
Houston, Texas, United States, 77401
Sponsors and Collaborators
LDR Spine USA
Investigators
Principal Investigator: Ralph Rashbaum, MD Texas Back Institute
  More Information

Responsible Party: LDR Spine USA ( Noah Bartsch, MS, Manager of Clinical Affairs )
Study ID Numbers: LDR-001, IDE Number G050212
Study First Received: October 18, 2006
Last Updated: March 24, 2008
ClinicalTrials.gov Identifier: NCT00389597  
Health Authority: United States: Food and Drug Administration

Study placed in the following topic categories:
Spinal Diseases
Musculoskeletal Diseases
Meloxicam
Bone Diseases

ClinicalTrials.gov processed this record on January 16, 2009